A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder

Atul Humar, Diane Hébert, H. Dele Davies, Abhinav Humar, Derek Stephens, Brenda O'Doherty, Upton Allen

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background. Transplant recipients who are Epstein-Barr virus (EBV)-seronegative and receive organs from seropositive donors (EBV D+/R-) are at increased risk for posttransplant lymphoproliferative disorder (PTLD) and may benefit from antiviral prophylaxis. We performed a multi-center trial assessing two different antiviral regimens and their effect on EBV replication. Methods. EBV D+/R- solid organ transplant recipients were randomized to receive either ganciclovir and placebo or ganciclovir and immunoglobulin (IG) for 3 months. Following this, patients were unblinded and IG patients received additional IG therapy until 6 months. EBV viral loads were done at least monthly. Results. Thirty-four patients (25 pediatric, 9 adult) completed the protocol (16 placebo; 18 IG). The incidence of a detectable viral load within the first year posttransplant was 13/16 (81.3%) in the ganciclovir arm vs. 13/18 (72.2%) in the ganciclovir and IG arm (P=0.8). Time to first detectable viral load, and time to high-level viral load were not significantly different. By repeated measures ANOVA analysis, and by estimation of viral load AUC, no significant effect of randomization group was observed on EBV viral loads. PTLD developed in 3 (8.8%) patients (all in IG arm; P=0.23). Conclusions. No significant difference in EBV viral load suppression was observed when ganciclovir was compared with ganciclovir and IG in high-risk EBV D+/R- patients.

Original languageEnglish (US)
Pages (from-to)856-861
Number of pages6
JournalTransplantation
Volume81
Issue number6
DOIs
StatePublished - Mar 1 2006

Fingerprint

Ganciclovir
Lymphoproliferative Disorders
Human Herpesvirus 4
Viral Load
Immunoglobulins
Arm
Antiviral Agents
Placebos
Passive Immunization
Virus Replication
Random Allocation
Area Under Curve
Analysis of Variance
Tissue Donors
Pediatrics
Transplants
Incidence

ASJC Scopus subject areas

  • Transplantation

Cite this

A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. / Humar, Atul; Hébert, Diane; Davies, H. Dele; Humar, Abhinav; Stephens, Derek; O'Doherty, Brenda; Allen, Upton.

In: Transplantation, Vol. 81, No. 6, 01.03.2006, p. 856-861.

Research output: Contribution to journalArticle

Humar, Atul ; Hébert, Diane ; Davies, H. Dele ; Humar, Abhinav ; Stephens, Derek ; O'Doherty, Brenda ; Allen, Upton. / A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. In: Transplantation. 2006 ; Vol. 81, No. 6. pp. 856-861.
@article{85debea14e0547199641d8dbd9f7818d,
title = "A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder",
abstract = "Background. Transplant recipients who are Epstein-Barr virus (EBV)-seronegative and receive organs from seropositive donors (EBV D+/R-) are at increased risk for posttransplant lymphoproliferative disorder (PTLD) and may benefit from antiviral prophylaxis. We performed a multi-center trial assessing two different antiviral regimens and their effect on EBV replication. Methods. EBV D+/R- solid organ transplant recipients were randomized to receive either ganciclovir and placebo or ganciclovir and immunoglobulin (IG) for 3 months. Following this, patients were unblinded and IG patients received additional IG therapy until 6 months. EBV viral loads were done at least monthly. Results. Thirty-four patients (25 pediatric, 9 adult) completed the protocol (16 placebo; 18 IG). The incidence of a detectable viral load within the first year posttransplant was 13/16 (81.3{\%}) in the ganciclovir arm vs. 13/18 (72.2{\%}) in the ganciclovir and IG arm (P=0.8). Time to first detectable viral load, and time to high-level viral load were not significantly different. By repeated measures ANOVA analysis, and by estimation of viral load AUC, no significant effect of randomization group was observed on EBV viral loads. PTLD developed in 3 (8.8{\%}) patients (all in IG arm; P=0.23). Conclusions. No significant difference in EBV viral load suppression was observed when ganciclovir was compared with ganciclovir and IG in high-risk EBV D+/R- patients.",
author = "Atul Humar and Diane H{\'e}bert and Davies, {H. Dele} and Abhinav Humar and Derek Stephens and Brenda O'Doherty and Upton Allen",
year = "2006",
month = "3",
day = "1",
doi = "10.1097/01.tp.0000202724.07714.a2",
language = "English (US)",
volume = "81",
pages = "856--861",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder

AU - Humar, Atul

AU - Hébert, Diane

AU - Davies, H. Dele

AU - Humar, Abhinav

AU - Stephens, Derek

AU - O'Doherty, Brenda

AU - Allen, Upton

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background. Transplant recipients who are Epstein-Barr virus (EBV)-seronegative and receive organs from seropositive donors (EBV D+/R-) are at increased risk for posttransplant lymphoproliferative disorder (PTLD) and may benefit from antiviral prophylaxis. We performed a multi-center trial assessing two different antiviral regimens and their effect on EBV replication. Methods. EBV D+/R- solid organ transplant recipients were randomized to receive either ganciclovir and placebo or ganciclovir and immunoglobulin (IG) for 3 months. Following this, patients were unblinded and IG patients received additional IG therapy until 6 months. EBV viral loads were done at least monthly. Results. Thirty-four patients (25 pediatric, 9 adult) completed the protocol (16 placebo; 18 IG). The incidence of a detectable viral load within the first year posttransplant was 13/16 (81.3%) in the ganciclovir arm vs. 13/18 (72.2%) in the ganciclovir and IG arm (P=0.8). Time to first detectable viral load, and time to high-level viral load were not significantly different. By repeated measures ANOVA analysis, and by estimation of viral load AUC, no significant effect of randomization group was observed on EBV viral loads. PTLD developed in 3 (8.8%) patients (all in IG arm; P=0.23). Conclusions. No significant difference in EBV viral load suppression was observed when ganciclovir was compared with ganciclovir and IG in high-risk EBV D+/R- patients.

AB - Background. Transplant recipients who are Epstein-Barr virus (EBV)-seronegative and receive organs from seropositive donors (EBV D+/R-) are at increased risk for posttransplant lymphoproliferative disorder (PTLD) and may benefit from antiviral prophylaxis. We performed a multi-center trial assessing two different antiviral regimens and their effect on EBV replication. Methods. EBV D+/R- solid organ transplant recipients were randomized to receive either ganciclovir and placebo or ganciclovir and immunoglobulin (IG) for 3 months. Following this, patients were unblinded and IG patients received additional IG therapy until 6 months. EBV viral loads were done at least monthly. Results. Thirty-four patients (25 pediatric, 9 adult) completed the protocol (16 placebo; 18 IG). The incidence of a detectable viral load within the first year posttransplant was 13/16 (81.3%) in the ganciclovir arm vs. 13/18 (72.2%) in the ganciclovir and IG arm (P=0.8). Time to first detectable viral load, and time to high-level viral load were not significantly different. By repeated measures ANOVA analysis, and by estimation of viral load AUC, no significant effect of randomization group was observed on EBV viral loads. PTLD developed in 3 (8.8%) patients (all in IG arm; P=0.23). Conclusions. No significant difference in EBV viral load suppression was observed when ganciclovir was compared with ganciclovir and IG in high-risk EBV D+/R- patients.

UR - http://www.scopus.com/inward/record.url?scp=33645651894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645651894&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000202724.07714.a2

DO - 10.1097/01.tp.0000202724.07714.a2

M3 - Article

C2 - 16570008

AN - SCOPUS:33645651894

VL - 81

SP - 856

EP - 861

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -